Clinical trials: Systemic Lupus
Systemic Lupus Erythematosus
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
The purpose of the SUNFLOWER study is to describe clinical outcomes, including DORIS remission, achieved following the initiation of anifrolumab 120 mg SC once weekly (QW) as add-on therapy to an anti-malarial, with or without…
- Trial name
- SUNFLOWER (NCT07430306)
- Testing
- Anifrolumab
- Where
- 107 sites in United States, Canada and 7 more
- Volunteers
- 245 people
- Sponsor
- AstraZeneca
Systemic Lupus Erythematosus (SLE)
CYCLONES - CYClophosphamide LOw Dose and No Extra Steroid
Glucocorticoids (GC) use has increased survival of patients with systemic lupus erythematosus (SLE), particularly in cases of nephritis and a more significant improvement to 80% with the introduction of therapy combined with…
- Trial name
- CYCLONES (NCT03492255)
- Testing
- Cyclophosphamide, Methylprednisolone, Prednisone
- Where
- 2 sites in Brazil
- Volunteers
- 49 people
- Sponsor
- University of Sao Paulo General Hospital
Childhood-onset Systemic Lupus Erythematous, ANCA-Associated Vasculitis (AAV)
Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders
Safety, tolerability and efficacy of Descarte-08 in children, adolescents and young adults with childhood-onset systemic lupus erythematosus, ANCA-associated vasculitis, juvenile myasthenia gravis, and juvenile dermatomyositis
- Conditions
- Childhood-onset Systemic Lupus Erythematous, ANCA-Associated Vasculitis (AAV), Juvenile Myasthenia Gravis, Juvenile Dermatomyositis
- Trial name
- NCT07089121
- Testing
- Descartes-08
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Cartesian Therapeutics
Systemic Lupus Erythematosus
Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST)
Systemic lupus erythematosus, also known as lupus or SLE, is a chronic, multisystem, autoimmune disease in which the body's internal system of defense attacks its own normal tissues.
- Trial name
- NCT00230035
- Testing
- Leukapheresis, Non-myeloablative high dose immunosuppressive therapy conditioning (HDIT), Autologous CD34+HPC transplantation (HSCT)
- Where
- 5 sites in United States
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Lupus Erythematosus, Systemic
A Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Mod-severe Systemic Lupus Erythematosus
This study aims to describe clinical outcomes, with focus on remission, achieved with use of anifrolumab participants with SLE on standard-of-care (as recommended by 2025 China SLE guidelines).
- Trial name
- LOTUS (NCT07751848)
- Testing
- Anifrolumab
- Where
- 74 sites in China
- Volunteers
- 417 people
- Sponsor
- AstraZeneca
Juvenile Idiopathic Arthritis, Rheumatoid Arthritis
Medical Follow-up of New Cases of Polyarthritis in Children and Young Adults
Population: Juvenile idiopathic arthritis (JIA), rheumatoid arthritis (RA) and seronegative / psoriatic / undifferentiated arthritis (UA), systemic lupus erythematosus (SLE) or diffuse systemic sclerosis dSS).
- Conditions
- Juvenile Idiopathic Arthritis, Rheumatoid Arthritis, Psoriatic Arthritis, Systemic Lupus Erythematosus
- Trial name
- NCT07000916
- Where
- Belgium
- Volunteers
- 1,000 people
- Sponsor
- Université Catholique de Louvain
Systemic Lupus Erythematosus
A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus
Primary objective: Safety and tolerability of NKX019, administered after lymphodepletion (LD). Secondary objectives: Assess clinical activity of NKX019 in subjects with systemic lupus erythematosus (SLE) with or without active…
- Trial name
- NCT06518668
- Testing
- NKX019, Cyclophosphamide LD
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Hospital for Special Surgery, New York
Lupus Nephritis
Clinical Trial Treatment in Lupus Nephritis
The treatment of lupus nephritis with cyclophosphamide and steroids changed the prognosis of lupus nephritis in the early '80s. In recent years, alternative regimens have appeared in both the induction and maintenance with…
- Trial name
- Csa-LES (NCT01299922)
- Testing
- cyclosporine +mycophenolic acid+prednison, Mycophenolic Acid + prednison
- Where
- Spain
- Sponsor
- Hospital Universitario Fundación Alcorcón
Systemic Lupus Erythematosus
Validation of the Lupus Low Disease Activity State (LLDAS) in the Asia Pacific Region
Lupus Low Disease Activity State (LLDAS) study is an international, multi-centre prospective study, developed by the Asia Pacific Lupus Collaboration (APLC) to investigate whether the attainment of LLDAS is associated with…
- Trial name
- APLCLLDAS (NCT03138941)
- Where
- 20 sites in Australia, China and 9 more
- Volunteers
- 5,000 people
- Sponsor
- Monash University
Lupus Erythematosus, Systemic
Double-Blinded, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Biochemical Activity of Intravenous Cpn10 Administration in Subjects With Mild to Moderate SLE.
The primary objective of the study is to evaluate the safety, tolerability, and efficacy of 4 weeks intravenous treatment with Cpn10 in subjects with mild to moderate active SLE.
- Trial name
- NCT01838694
- Testing
- Ala-Cpn10
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- Invion, Inc.
Systemic Lupus Erythematosus
Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users
PRIMULA Preg (Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users) is a prospective, observational cohort study designed to evaluate the association between anifrolumab exposure during pregnancy…
- Trial name
- PRIMULA_Preg (NCT06659029)
- Testing
- Anifrolumab
- Where
- United States
- Volunteers
- 442 people
- Sponsor
- AstraZeneca
HLA Antibodies, Systemic Lupus Erythematosus
HLA Antibodies in Systemic Lupus Erythematosus
Patients suffering from autoimmune diseases show false-positive results when anti-HLA antibodies are identified. This false positivity makes it difficult to obtain an organ transplant based on immunological compatibility (absence…
- Trial name
- LEDHLA (NCT06921239)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
SLE Glomerulonephritis Syndrome, WHO Class V
ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis
This is an open-label, randomized, multi-center, Phase IV study of Acthar Gel in patients with biopsy-proven membranous (Class V) lupus nephritis (LN) aimed at providing proof-of-concept data that Acthar is a safe and effective…
- Trial name
- NCT01926054
- Testing
- Acthar gel
- Where
- United States
- Sponsor
- Ohio State University
Lupus Erythematosus, Scleroderma
Clinico-biological Collection to Investigate the Physiopathology of Systemic Autoimmune Diseases
The aim of this project is to start a biological and clinical collection of patients presenting systemic autoimmune disease. This collection will provide appropriate biological samples to identify new biomarkers and to be…
- Conditions
- Lupus Erythematosus, Scleroderma, Myositis, Vasculitis
- Trial name
- ESSAi (NCT05251415)
- Testing
- Blood sampling
- Where
- France
- Volunteers
- 3,000 people
- Sponsor
- University Hospital, Toulouse
Systemic Lupus Erythematosus
Safety and Efficacy of Telitacicept in the Treatment of Systemic Lupus Erythematosus (SLE)
Systemic lupus erythematosus (SLE) is a highly specific autoimmune disease that involves multiple systems due to abnormal immune activation.
- Trial name
- NCT06458972
- Where
- China
- Volunteers
- 139 people
- Sponsor
- Tongji Hospital
Systemic Lupus Erythematosus, Rheumatoid Arthritis
Breaking Implicit Bias Habits: An Individuation Pilot Study In Rheumatology
The first aim of this study is to test the efficacy of a real-time provider-based individuation intervention to improve the receipt of high-quality rheumatic disease care among Black/African American and lower socioeconomic…
- Conditions
- Systemic Lupus Erythematosus, Rheumatoid Arthritis, Inflammatory Arthritis, Osteoarthritis
- Trial name
- NCT05116163
- Testing
- Individuation Intervention plus implicit bias educational modules, Implicit bias educational modules
- Where
- 2 sites in United States
- Volunteers
- 201 people
- Sponsor
- Brigham and Women's Hospital
Systemic Lupus Erythematosus, Lupus Nephritis
Effectiveness of Mycophenolate Mofetil Combined With Tacrolimus for Steroid Tapering in Systemic Lupus Erythematosus
The goal of this clinical trial is to determine whether mycophenolate mofetil(MMF) combined with tacrolimus(TAC) can maintain remission in patients with lupus nephritis (LN) who have reached treatment targets after steroid…
- Trial name
- NCT05916781
- Testing
- Mycophenolate Mofetil, Tacrolimus, Glucocorticoid
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Chinese SLE Treatment And Research Group
Systemic Lupus Erythematosus
The Diagnostic Utility of T Immunoglobulin G and T Immunoglobulin M Biomarkers in Patients With Systemic Lupus Erythematosus Disease : Associations With Disease Activity and Damage
The SLE is heterogeneous multisystem autoimmune disease with complex pathogenesis involves multiple cellular components of the innate and adaptive immune systems, presence of autoantibodies and immune complexes, engagement of the…
- Trial name
- NCT07136337
- Testing
- 4 ml. of fresh venous blood will be collected from each patient on EDTA tube and will be used for detection of the following : T cell immunoglobulin G ( TIgG) and T cell immunoglobulin M (TIgM) by
- Where
- Egypt
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Assiut University
Lupus Nephritis, Systemic Lupus Erythematosus
Biomarker Development for Autoimmune Disorders Involving the Kidneys
SILENT-LN is a prospective observational cohort study of adults with systemic lupus erythematosus, including participants with no renal involvement, suspected renal involvement, active lupus nephritis, previous lupus nephritis…
- Trial name
- SILENT_LN (NCT07666711)
- Testing
- Longitudinal Blood and Urine Biomarker Monitoring
- Where
- Norway
- Volunteers
- 500 people
- Sponsor
- Oslo University Hospital
Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc)
CT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory/Progressive Systemic Sclerosis (SSc)
A Clinical Study Exploring CT1190B in the treatment of patients with moderate to severe refractory systemic lupus erythematosus (SLE) or refractory/progressive systemic sclerosis (SSc)
- Trial name
- NCT06822881
- Testing
- CAR-T Therapy
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Beijing GoBroad Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.